Recursion Pharmaceuticals, Inc. RXRX Other — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Recursion Pharmaceuticals, Inc.’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s other — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s other — total revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) reported other — total revenue of $0 in Q4 2025.
- How has Recursion Pharmaceuticals, Inc.'s other — total revenue changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s other — total revenue decreased by 100.0% year-over-year, from $81.75K to $0.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s other — total revenue?
- Over 2 years (2023 to 2025), Recursion Pharmaceuticals, Inc.'s other — total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $769K to $0.
- What does other — total revenue mean?
- This metric represents the total revenue generated from geographic regions or business activities classified as 'Other' outside of the company's primary operational markets. It tracks the contribution of secondary or emerging territories to the firm's overall top-line performance. Monitoring this helps investors assess the company's geographic diversification and the scalability of its business model in non-core markets.